Skip to main content
Premium Trial:

Request an Annual Quote

Holmes Trial Delay Sought

Elizabeth Holmes, the founder and former CEO of Theranos, is seeking to push back the start of her trial, scheduled for July, as she is pregnant and expects to give birth then, the Wall Street Journal reports.

Holmes was indicted in 2018 on charges of wire fraud and conspiracy to commit wire fraud. The Mercury News reported last year that another fraud charge had been added stemming from a patient's testing results. Theranos once claimed to be able to run a range of blood tests using a small amount of blood from a finger prick. But a series of articles in the Journal beginning in 2015 called the company's ability to run those tests in to question and regulators uncovered testing issues at the company, which closed in 2018.

Prosecutors have alleged that Holmes and Ramesh 'Sunny' Balwani, the company's former president, committed fraud as they knew Theranos could not perform the tests as claimed. Holmes and Balwani have pleaded not guilty.

According to CNBC, her lawyers are seeking to push the start of her trial back to the end of August 2021. Her trial was previously postponed due to the COVID-19 pandemic.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.